Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: hyperinsulinemic-euglycemic clamp Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

NCT06320951
View directory record Official record
Conditions
Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions
Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

NCT01660009
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glycemic clamping
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers

NCT01433705
View directory record Official record
Conditions
Heart Disease
Interventions
Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional

Effect of Physiologic Insulin Administration on Cognition

NCT06424652
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood draws, Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test, Resting Metabolic Rate (RMR)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
65 Years to 75 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional

Effect of Pulsatile Hormone Administration on Insulin Action

NCT06216665
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Continuous Insulin administration during hyperinsulinemic euglycemic clamp test, Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hypoglycemia and Autonomic Nervous System Function

NCT01816893
View directory record Official record
Conditions
Hypoglycemia
Interventions
Hypoglycemic hyperinsulinemic clamp, Euglycemic hyperinsulinemic clamp
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hypoglycemic Clamp
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metabolomic Analysis of Hepatic Insulin Resistance

NCT01833403
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Hyperinsulinemic-euglycemic clamp
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 24, 2026, 10:15 AM EDT
Withdrawn No phase listed Observational

Insulin Resistance in Type I Diabetes in Pediatric Care

NCT00946426
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Clamp
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
9 Years to 23 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypoglycemia and Autonomic Nervous System Function-B

NCT03429946
View directory record Official record
Conditions
Hypoglycemia, Healthy
Interventions
Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance

NCT07516509
View directory record Official record
Conditions
Insulin Resistance
Interventions
VO2 Max, DEXA, Peripheral Microvascular Reactivity, Skeletal Muscle Insulin Sensitivity, Non-Oxidative Glucose Disposal, Muscle tissue Biopsy
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response of Epinephrine

NCT02692313
View directory record Official record
Conditions
Diabetes Complications
Interventions
Epinephrine, Saline infusion
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 24, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

NCT07361874
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
Interventions
Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 24, 2026, 10:15 AM EDT
Recruiting Phase 1 Interventional

Metabolic Effects of Angiotensin-(1-7)

NCT02646475
View directory record Official record
Conditions
Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 24, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Impact of Acute Exercise on Vascular Insulin Sensitivity in Metabolic Syndrome

NCT03894527
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Single Bout of Exercise, Control Condition
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 24, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 4 Interventional

Molecular Mechanisms of Type 2 Diabetes Mellitus

NCT00816218
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

RYGB and the Gastric Adipose Axis

NCT01474785
View directory record Official record
Conditions
Obesity
Interventions
human ghrelin, very low calorie diet, Hyperinsulinemic/Euglycemic Clamp
Drug · Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 24, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 24, 2026, 10:15 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Studies of Insulin and Glucagon Action in the Liver

NCT07300982
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Glucagon, Saline (placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 24, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
View directory record Official record
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 24, 2026, 10:15 AM EDT